VivoSeq
Ophthalmology

Dry Eye Disease (DED)

4

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Dry Eye Disease (DED) is an early-stage landscape with 4 programs across 1 company. The most active players are Eli Lilly. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 43% of 7 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting4 · 80%
Completed1 · 20%

Clinical Trials

Trial Activity

A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype
Recruiting·OOculis·Preclinical·NCT07548632·160 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of HUC1-394 in Participant With Dry Eye Disease
Recruiting·HHuons Co., Ltd.·Phase 2·NCT07656688·150 enrolled
A Randomized, Investigator-Masked, Single-Center Study Evaluating Tolerability, Symptomatic Improvement, and Visual Functional Outcomes With the Use of Over-the-Counter Lubricating Eye Drops in Subjects With Dry Eye Disease
Recruiting·AAndover Research Eye Institute·Approved·NCT07676084·60 enrolled
A 12-Week, Phase 2, Multicenter, Randomized, Double-Masked, Vehicle Controlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate the Efficacy and Safety of DFL24498 0.08% Topical Ophthalmic Solution Versus Vehicle in Participants With Dry Eye Disease
Recruiting·—·Phase 2·NCT07503886·417 enrolled
A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study
Completed·LLaboratoires Thea·N/A·NCT07234318·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)